PSA as an intermediate end point in clinical trials

被引：9

作者：

Attard, Gerhardt ^{[1
,2
]}

de Bono, Johann S. ^{[1
,2
]}

机构：

[1] Inst Canc Res, Med Sect, Sutton SM2 5PT, Surrey, England

[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

来源：

NATURE REVIEWS UROLOGY | 2009年 / 6卷 / 09期

基金：

英国医学研究理事会;

关键词：

PROSTATE-SPECIFIC ANTIGEN; CIRCULATING TUMOR-CELLS; WORKING GROUP; CANCER; SURVIVAL; RECOMMENDATIONS; SURROGACY;

D O I：

10.1038/nrurol.2009.130

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The 2009 study by Hussain et al. showed that a PSA-based intermediate end point might be useful in clinical trials of advanced prostate cancer. However, overall survival (OS) will remain the required end point of phase III studies and the search for a true, robust surrogate of oS to accelerate drug development continues.

引用

页码：473 / 475

页数：4

共 10 条

[1] Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer [J].

Armstrong, Andrew J. ;

Garrett-Mayer, Elizabeth ;

Yang, Yi-Chun Ou ;

Carducci, Michael A. ;

Tannock, Ian ;

de Wit, Ronald ;

Eisenberger, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3965-3970

[2] Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Swermenhuis, Joost F. ;

Olmos, David ;

Reid, Alison H. M. ;

Vickers, Elaine ;

A'Hern, Roger ;

Levink, Rianne ;

Coumans, Frank ;

Moreira, Joana ;

Riisnaes, Ruth ;

Oommen, Nikhil Babu ;

Hawche, George ;

Jameson, Charles ;

Thompson, Emilda ;

Sipkema, Ronald ;

Carden, Craig P. ;

Parker, Christopher ;

Dearnaley, David ;

Kaye, Stan B. ;

Cooper, Colin S. ;

Molina, Arturo ;

Cox, Michael E. ;

Terstappen, Leon W. M. M. ;

de Bono, Johann S. .

CANCER RESEARCH, 2009, 69 (07) :2912-2918

[3] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].

Bubley, GJ ;

Carducci, M ;

Dahut, W ;

Dawson, N ;

Daliani, D ;

Eisenberger, M ;

Figg, WD ;

Freidlin, B ;

Halabi, S ;

Hudes, G ;

Hussain, M ;

Kaplan, R ;

Myers, C ;

Oh, W ;

Petrylak, DP ;

Reed, E ;

Roth, B ;

Sartor, O ;

Scher, H ;

Simons, J ;

Sinibaldi, V ;

Small, EJ ;

Smith, MR ;

Trump, DL ;

Vollmer, R ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467

[4] Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?: Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals [J].

Collette, L ;

Burzykowski, T ;

Carroll, KJ ;

Newling, D ;

Morris, T ;

Schröder, FH .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6139-6148

[5] Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer [J].

de Bono, Johann S. ;

Scher, Howard I. ;

Montgomery, R. Bruce ;

Parker, Christopher ;

Miller, M. Craig ;

Tissing, Henk ;

Doyle, Gerald V. ;

Terstappen, Leon W. W. M. ;

Pienta, Kenneth J. ;

Raghavan, Derek .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6302-6309

[6] Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer [J].

Halabi, Susan ;

Vogelzang, Nicholas J. ;

Ou, San-San ;

Owzar, Kouros ;

Archer, Laura ;

Small, Eric J. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) :2766-2771

[7] Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 [J].

Hussain, Maha ;

Goldman, Bryan ;

Tangen, Cathy ;

Higano, Celestia S. ;

Petrylak, Daniel P. ;

Wilding, George ;

Akdas, Atif M. ;

Small, Eric J. ;

Donnelly, Bryan J. ;

Sundram, Subramanian Kanaga ;

Burch, Patrick A. ;

DiPaola, Robert S. ;

Crawford, E. David .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) :2450-2456

[8] Speeding up the evaluation of new agents in cancer [J].

Parmar, Mahesh K. B. ;

Barthel, Friederike M. -S. ;

Sydes, Matthew ;

Langley, Ruth ;

Kaplan, Rick ;

Eisenhauer, Elizabeth ;

Brady, Mark ;

James, Nicholas ;

Bookman, Michael A. ;

Swart, Ann-Marie ;

Qian, Wendi ;

Royston, Patrick .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (17) :1204-1214

[9] Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 [J].

Petrylak, DP ;

Ankerst, DP ;

Jiang, CS ;

Tangen, CM ;

Hussain, MHA ;

Lara, PN ;

Jones, JA ;

Taplin, ME ;

Burch, PA ;

Kohli, M ;

Benson, MC ;

Small, EJ ;

Raghavan, D ;

Crawford, ED .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (08) :516-521

[10] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group [J].

Scher, Howard I. ;

Halabi, Susan ;

Tannock, Ian ;

Morris, Michael ;

Sternberg, Cora N. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Higano, Celestia ;

Bubley, Glenn J. ;

Dreicer, Robert ;

Petrylak, Daniel ;

Kantoff, Philip ;

Basch, Ethan ;

Kelly, William Kevin ;

Figg, William D. ;

Small, Eric J. ;

Beer, Tomasz M. ;

Wilding, George ;

Martin, Alison ;

Hussain, Maha .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1148-1159

← 1 →